Business Wire

StrongPoint’s Order Picking Solution Delivers Unprecedented Levels of Efficiency to Accelerate Grocers’ E-Commerce Capabilities

23.6.2021 09:00:00 EEST | Business Wire | Press release

Share

StrongPoint ASA, a leading European grocery retail solution provider, today announces its grocery e-commerce picking solution, designed specifically for grocery retailers looking for fast, hyper-efficient and scalable e-commerce logistics solutions. The Strongpoint solution suite delivers industry-leading efficiency rates with many in-store associates averaging ~240 items picked per labor hour across all product categories, compared with common industry standards of 60-65 items per hour.

Hosted on StrongPoint’s cloud-based SaaS e-commerce platform, the Order Picking solution helps retailers capitalize on the growing opportunity of online grocery, driving greater efficiency and higher productivity rates. It also reduces labor costs associated with the fulfillment of online orders, while enhancing customer convenience and protecting margins.

StrongPoint launched its first Order Picking solution more than 20 years ago. Since then, it has undergone countless iterations, changes and updates based on customer feedback over two decades of usage by thousands of pickers in multiple countries. A key benefit of StrongPoint’s cloud-based solution is that grocery retailers receive continuous updates as the team finds new opportunities to drive efficiency gains.

Since the start of the pandemic, Bain estimates adoption of online grocery in the US and Western Europe has accelerated between two and five years and this sustained demand is set to continue2. Despite the explosion in demand, both for grocery e-commerce and q-commerce, retailers have struggled to make online grocery profitable, with the high cost of labor hours allocated to picking and the fulfillment of e-commerce orders ebbing away at already squeezed margins.

StrongPoint’s solution was born out of 35+ years’ experience in responding to the rapidly evolving needs of leading grocery retailers across multiple European countries. Its grocery e-commerce Order Picking solution delivers unprecedented efficiencies compared to orders that are picked manually, by empowering staff with its proprietary software technology.

Many of StrongPoint’s grocery retail customers who are utilizing the full functionalities of the solution are able to reach average in-store picking rates of ~240 items per labor hour across all product categories, compared with a common industry standard of 60-65 items per labor hour when using traditional solutions. In addition, StrongPoint’s Order Picking solution averages 99.99% accuracy, making it on par with leading fully automated grocery fulfillment solutions.

Its hyper-efficient orchestration technology customizes the picking route for the store associate, creating the most effective order sequencing for picking, based on the unique layout and footprint of each store. Other standard features include picking by temperature zones, multiple solutions for age-restricted items and substitution options.

The solution, which can be deployed in large and small format settings with the option of using Zebra hardware devices for maximum efficiency, includes multi-zone and multi-order picking capabilities to drive even greater efficiencies. It can integrate with in-built store hardware, such as electronic shelf labels (ESLs), allowing store associates to “pick to light” to increase speed and order accuracy. In addition, there is the option of integrating a smart trolley that has been purpose-built for maximum ergonomic efficiency. Data inputs at each stage of the picking process – from preparing the trolley to the picking, weighing, and bagging of products – create a continuous feedback loop, so ergonomic improvements can be made to drive further efficiencies, speed and accuracy.

“We are proud to unveil our latest technology solution, specifically designed to help grocery retailers leverage their stores and cater to the exponential growth of e-commerce,” said Jacob Tveraabak, CEO at StrongPoint. “Having worked with grocery retailers for over three decades, we understand the importance of driving speed, efficiency and scalability across their operations in the stores – and that was intrinsic in how we developed the latest iteration of our grocery e-commerce Order Picking solution.”

-ENDS-

Notes to editors

StrongPoint is a retail technology company that provides solutions to make shops smarter, shopping experiences better and online grocery shopping more efficient.

With over 450 employees in Norway, Sweden, the Baltics and Spain and, together with a wide partner network, StrongPoint supports businesses in more than 20 countries.

StrongPoint is headquartered in Norway and is listed on the Oslo Stock Exchange.

For more information, visit https://www.strongpoint.com/


1 https://www.mwpvl.com/MWPVL_International_-_Micro_Fulfillment_Centers_-_Passing_Fad_or_Permanent_Market_Shift.pdf
2 https://www.bain.com/insights/the-next-five-years-in-online-grocery-snap-chart/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Catherine Seeds
Ketner Group Communications (US)
catherine@ketnergroup.com
512.947.4062

Sarah Cole
Fieldworks Marketing (UK)
Sarah.cole@fieldworksmarketing.co.uk
0845 034 5602

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye